Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial - Wikidata - wikimedia - TriplyDB

Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial

Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial

http://www.wikidata.org/entity/Q37267547

about

Modulation of deregulated chaperone-mediated autophagy by a phosphopeptide Key issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implications Use of biologics in SLE: a review of the evidence from a clinical perspective HSPA8/HSC70 chaperone protein: structure, function, and chemical targeting.Immunotherapies in Late-Stage Development for Patients With Severe SLE and/or Lupus Nephritis.Peptides and peptidomimetics as immunomodulators.Pharmacological regulators of autophagy and their link with modulators of lupus disease Epigenetics of autoantigens: new opportunities for therapy of autoimmune diseases.The importance of implementing proper selection of excipients in lupus clinical trials Manipulating autophagic processes in autoimmune diseases: a special focus on modulating chaperone-mediated autophagy, an emerging therapeutic target.Diagnosis and risk stratification in patients with anti-RNP autoimmunity.Mapping epitopes of U1-70K autoantibodies at single-amino acid resolution.Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus.Drugs in early clinical development for Systemic Lupus Erythematosus.Metabolic Factors that Contribute to Lupus Pathogenesis Conservation of pathogenic TCR homology across class II restrictions in anti-ribonucleoprotein autoimmunity: extended efficacy of T cell vaccine therapy.Ten developments in the use of biologicals for systemic lupus erythematosus.Emerging view of autophagy in systemic lupus erythematosus.Systemic lupus erythematosus: a therapeutic challenge for the XXI century.Emerging biological therapies for systemic lupus erythematosus.Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers.Multifunctional adamantane derivatives as new scaffolds for the multipresentation of bioactive peptides.The evolution of drug discovery in systemic lupus erythematosus.Nanomaterials, Autophagy, and Lupus Disease.What can we learn from systemic lupus erythematosus pathophysiology to improve current therapy?Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art.Emerging therapies in systemic lupus erythematous: from clinical trial to the real life.Ubiquitin-like protein MNSFβ noncovalently binds to molecular chaperone HSPA8 and regulates osteoclastogenesis.Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus.Recent advances and current state of immunotherapy in systemic lupus erythematosus.Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials.Update on Biologic Therapies for Systemic Lupus Erythematosus.Autophagy: controlling cell fate in rheumatic diseases.T-cell-directed therapies in systemic lupus erythematosus.Regulatory T Cells in SLE: Biology and Use in Treatment.Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus.Novel Treatments in Lupus.Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective.Capability of Neutrophils to Form NETs Is Not Directly Influenced by a CMA-Targeting Peptide The human VGF-derived bioactive peptide TLQP-21 binds heat shock 71 kDa protein 8 (HSPA8)on the surface of SH-SY5Y cells

P2860

Q24320133-2878FB75-2ADB-456C-A27D-7ABF5D88EF97 Q26775756-14F4F7FA-AD81-4DD4-874C-9B85984169F1 Q26783652-9D39CBD9-528C-4677-B013-24DB2BC831ED Q30354473-FB3242BC-DFD2-48C6-B709-361D99F35C10 Q33714219-275A47F2-EBB2-4CFB-8BE6-F1B6D1ACCBB7 Q34359984-7AA7FE1C-B661-4BBD-90C1-DC3F9744023E Q34402759-97D32E8D-CE83-49AB-8D10-9FF8BCD65DED Q34463063-860B420C-037A-4CD4-BA58-3369A94DFD8F Q34512785-6472F9C3-CFC5-4C69-8499-7D70310ACF16 Q35622999-AE1297EB-7007-4431-9E66-1F2D25161056 Q35930490-61158E98-9074-44B8-80DD-9CB54553EFD6 Q36751110-7509BDFB-37FB-4B53-8656-07C9D59F8D50 Q37150868-D84D7869-C156-4D9A-A691-5BAA45AB8166 Q37324772-6F882492-66F5-4339-B571-314D5558C0C0 Q37612885-556A64CE-41A4-4412-B108-D1E2A03E068E Q37726019-37044963-6DC0-41D3-BE48-D04DC72DFD69 Q38105959-20C80191-B414-421D-A5B8-6C80E68FF1DA Q38189443-9E9613FF-6669-4567-98AC-2B4DAAFCF0D6 Q38191835-C97F2D4B-C7CC-4A99-A180-1A760816584D Q38192683-9B784034-E8A7-4C26-AF04-74E69B4B0A99 Q38247180-D9187078-9199-4B67-9F34-32043F0C24A5 Q38275427-4190F63D-DE94-4AEB-A632-7AD6BD9E897D Q38540167-6DFA25B4-F2FD-4CCE-97BC-F39EEEA567A8 Q38551098-D7A1EA48-2288-4039-BC7C-88DE3CD2AAAF Q38590248-EC51B0E0-EBAE-4656-9ABE-F0634D2362DC Q38690844-36DB14B4-02AD-4D3B-9CB4-C0A290F8DDB3 Q38747383-0D91DDCF-08F0-461A-A87C-D8A1968DC895 Q38748825-E95D63A1-4F2B-4BF0-98D2-D4B9BD2F9DB4 Q38771936-CF00F3B3-FA7C-4486-B851-F2DFECC2A36F Q38794663-057BF958-C7E2-43B6-B4DB-4E1470E752DE Q38840646-11DAF160-D2BC-44FD-B431-A38350E77E5F Q38864797-0C27CC3B-4A77-4895-ACA6-4ED3A6BA2417 Q38873681-C5FAA337-F8E6-4B5C-85BF-C68864AC215B Q38920440-644969A5-E110-4D58-B46D-23E232AF6146 Q38972466-538D5310-B913-4AE9-9010-B73D3AF1543F Q39150632-65829668-FC4A-4B63-931D-CF92828A9347 Q39164953-C4AF71AC-7368-491A-9019-824856E0CE26 Q39379152-24B139BD-0AD4-4049-8FD5-7E198F783541 Q42327818-2BA2171C-A1BB-4E65-8B21-760D7DE6694A Q42362126-6FBB4AAD-7C44-427E-AAB9-C71C35F89DDC

P2860

Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial

http://www.wikidata.org/entity/Q37267547

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Lupuzor/P140 peptide in patien ...... olled phase IIb clinical trial

@en

Lupuzor/P140 peptide in patien ...... lled phase IIb clinical trial.

@nl

type

label

Lupuzor/P140 peptide in patien ...... olled phase IIb clinical trial

@en

Lupuzor/P140 peptide in patien ...... lled phase IIb clinical trial.

@nl

prefLabel

Lupuzor/P140 peptide in patien ...... olled phase IIb clinical trial

@en

Lupuzor/P140 peptide in patien ...... lled phase IIb clinical trial.

@nl

P1433

Q37267547-964D22D2-231A-4917-8A54-9A7BD6CD1C93

P1476

Q37267547-06A0D3B7-1474-454A-A0E9-09A5393E667B

P2093

Q37267547-05D89E8B-C6A5-4A1F-A64C-68821109A763

Q37267547-72968052-B323-482E-B328-A0A24E510861

Q37267547-75A76D21-F3D0-42E0-9DAB-5CEF4C68AD8A

Q37267547-D6A9DADD-27C7-4F5D-B09C-C41905822CFF

Q37267547-E5DC98FB-4791-40BC-87F2-66BC0598DD28

P2860

Q37267547-170B8F3E-0AD8-48D8-AE6B-B1E190D6F319

Q37267547-25858291-249E-408F-BD3B-0A2104C81006

Q37267547-2AEC1ACF-702B-4ABC-9E8D-5DFD3C735B16

Q37267547-309D5260-E823-42F2-BD38-6958B09116A6

Q37267547-4BDE1385-F286-4026-A019-53306FA0061C

Q37267547-6D371002-B851-4DA4-8A72-7BA2381915A2

Q37267547-7054883F-123A-4665-82E6-5C86AD9648CA

Q37267547-73B8B521-D444-450E-AE4A-E5F8A3FB8EDA

Q37267547-94B56729-4ABA-4D5A-AE0B-CDC8A7B610ED

Q37267547-AA7D2FB9-C043-4CEF-B94A-D2E2C54244DE

P304

Q37267547-66FFA65D-9333-4907-9CBC-12B3DA3F5A16

P31

Q37267547-72543C40-2016-4A90-BAD4-4FF27157AC5C

P356

Q37267547-B257D469-66CC-4153-8D79-B2046521B7A4

P407

Q37267547-409D30C5-8A49-4599-BA4C-43B7AD6A579E

P433

Q37267547-64BC4365-2DD5-48EC-AD02-99AFAE6EF827

P478

Q37267547-03B3DAFD-F2A3-45CF-8643-C42E8E05D9FF

P577

Q37267547-2358DACC-2005-40DF-BE8D-07C24A6188F5

P5875

Q37267547-482F3BBA-01BA-411F-9909-49557DD38174

P698

Q37267547-E40770F1-E222-43A2-BD4D-02A53B6D688C

P921

Q37267547-2A6C3EC7-A51C-4B8A-8385-A37BB8A61F95

Q37267547-EA6FE179-22FF-4206-8ABE-395EA0049F7E

P932

Q37267547-2439717A-1004-48E9-ADAB-E8DB7DC623ED

P356

ANNRHEUMDIS-2012-202460

P1433

Annals of the Rheumatic Diseases

P1476

Lupuzor/P140 peptide in patien ...... olled phase IIb clinical trial

@en

P2093

Hugo R Scherbarth

http://www.w3.org/2001/XMLSchema#string

Juan Jesus Gomez-Reino

http://www.w3.org/2001/XMLSchema#string

Oscar Luis Rillo

http://www.w3.org/2001/XMLSchema#string

Robert Zimmer

http://www.w3.org/2001/XMLSchema#string

Sylviane Muller

http://www.w3.org/2001/XMLSchema#string

P2860

A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus

The Spliceosomal Phosphopeptide P140 Controls the Lupus Disease by Interacting with the HSC70 Protein and via a Mechanism Mediated by γδ T Cells

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

The 1982 revised criteria for the classification of systemic lupus erythematosus

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes

Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial.

HSC70 blockade by the therapeutic peptide P140 affects autophagic processes and endogenous MHCII presentation in murine lupus.

Challenges in bringing the bench to bedside in drug development for SLE.

P304

1830-1835

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ANNRHEUMDIS-2012-202460

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233745998

http://www.w3.org/2001/XMLSchema#string

P698

23172751

http://www.w3.org/2001/XMLSchema#string

P921

P932

3812851

http://www.w3.org/2001/XMLSchema#string